Floatz Rating
B63/100
Confidence
Indicative
Sponsor
Hospital Universitari Vall d'Hebron Research Institute
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
51Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07590648CT.gov Early Discontinuation of Antibiotics in Paediatric High-risk Febrile Neutropenia | — | Not Yet Recruiting | — | — | — |
NCT00445497CT.gov Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia | — | Unknown | — | — | — |
NCT00062231CT.gov Moxifloxacin Compared With Ciprofloxacin/Amoxicillin in Treating Fever and Neutropenia in Patients With Cancer | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Neutropenia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Ciprofloxacin (this asset) | Hospital Universitari Vall d'Hebron Research Institute | Approved | B · 63 |
| f-627 | EVIVE Biotechnology | P3 | BBB |
| Pegfilgrastim | Affiliated Hospital of North Sichuan Medical College | P4 | BBB |
| Nivestim | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | P4 | BBB |
| Cefepime | Hospital Universitari Vall d'Hebron Research Institute | P4 | BB |
| Docetaxel | Spectrum Pharmaceuticals, Inc | P3 | BB |
| Spi-2012 | Spectrum Pharmaceuticals, Inc | P3 | BB |
| Cyclophosphamide | Spectrum Pharmaceuticals, Inc | P3 | BB |
| Posaconazole | Merck Sharp & Dohme LLC | P4 | BB |
+42 more in the Neutropenia cohort
Other indications for Ciprofloxacin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Bronchiectasis | — | P4 | BBB · 76 |
| Infectious Disease | — | P4 | BBB · 72 |
| Chronic Obstructive Pulmonary Disease | — | P4 | BB · 66 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Ciprofloxacin in Neutropenia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ciprofloxacin-neutropenia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →